200 results found | searching for "prostate"
-
-
Looking for the best urology hospital in East Delhi? Aarogya Hospital offers advanced, compassionate care for all your urological needs—from kidney stones and prostate issues to urinary infections and male infertility. Our expert urologists use state-of-the-art technology and minimally invasive procedures to ensure faster recovery and better outcomes. With a patient-first approach, modern facilities, and round-the-clock support, we’re proud to be the trusted choice for thousands of families in East Delhi. Book your appointment today and experience world-class urology care close to home! Read more - https://www.aarogyahospital.com/urology/ -
-
India's biggest store getsetwild is giving best quality anal toys for men and women at an affordable price. Shop for original and branded anal toys with fast delivery from GetSetWild. Here you can get many anal toys such as anal beads, butt plug, prostate massager, etc. GetSetWild provides 24hr customer service. One can WhatsApp at 8122309316 anytime. visit now: https://getsetwild.com/adult/anal-toys/ -
-
Prostate is a gland in males and can be treated well if diagnosed early. It can be screened by simple tests like PSA. That is, the common forms of therapeutic intervention are surgical, radiation, and hormonal therapy. https://gomedii.com/sites/enquiry/best-oncologists-in-chennai-cancer-specialist-in-chennai.html?lang=en
-
-
Global Interventional Oncology Market Worth $2.9 Billion by 2026: Key Insights and Analysis https://www.marketsandmarkets.com/Market-Reports/interventional-oncology-market-203687164.html The global interventional oncology market size is expected to grow from USD 1.9 billion in 2020 to USD 2.9 billion in 2026, at a CAGR of 6.8% during the forecast period. Technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising incidence of infectious diseases, and increased funding and public-private investments are some of the key factors driving the growth of the interventional oncology market. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164 Based on product, the interventional oncology market is segmented into ablation devices, embolization devices, and support devices. The embolization devices segment accounted for the largest share of 63.8% of the interventional oncology market in 2020. The large share of this segment can be attributed to the rising prevalence of cancer, product enhancements, and the increasing adoption of Yttrium-90 radioembolic agents in emerging countries. Ongoing technological advancements in the field of oncology, rising prevalence of cancer, high healthcare expenditure, are the major factors supporting market growth. Based on procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2020, the TARE/SIRT procedures segment accounted for the largest market share, mainly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures). Based on cancer type, the interventional oncology market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). The liver cancer segment accounted for the largest share of 63.8% of the interventional oncology market in 2020. The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology. Based on end users, the interventional oncology market is segmented into hospitals, ambulatory surgery centers, and research & academic institutes. Hospitals accounted for the largest share of the market in 2020. The large share of this end-user segment can be attributed to the presence of advanced ICUs & emergency wards in hospitals and the increasing number of surgical procedures performed in hospitals. The interventional oncology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America was the largest regional market for interventional oncology, with a share of 43.2%. Factors such as continuous development and commercialization of novel interventional oncology products and favorable reimbursements & insurance coverage drive the market for interventional oncology in North America. The Asia Pacific is estimated to be the fastest-growing regional market for interventional oncology. This is due to the rising patient population increasing GDP and healthcare expenditure and growing public awareness about various surgical treatments. Major Players: Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea). Recent Developments In 2021, Boston Scientific (US) launched Launched the TheraSphere Y-90 Glass Microspheres In 2018, Merit Medical Systems (US) launched the Preclude IDeal Hydrophilic Sheath Introducer in EMEA markets In 2018, IMBiotechnologies (US) launched ‘Ekobi 500 Embolization Microspheres’ with an enhanced feature of detectability using ultrasound technology. In 2018, Medical City and distributor Gulf Medical Company to install the first IMRIS Surgical Theatre in Saudi Arabia. In 2018, Medtronic (Ireland) launched its OptiSphere embolization spheres designed for hypervascular tumor embolization in the US -
-
2027 Outlook: Diagnostic Imaging Services Market to Achieve $702.6 Billion https://www.marketsandmarkets.com/Market-Reports/diagnostic-imaging-service-market-17157849.html The diagnostic imaging services market is projected to reach USD 702.6 billion by 2027 from USD 549.0 billion in 2022, at a CAGR of 5.1% during the forecast period. Factors such as increasing prevalance of chronic diseases, rapidly growing geriatric population, technological adavancements in imaging modalities, and rising demand for early diagnosis of diseases are anticipated to propel the growth of market during the forecast period. Howerevr, rising cost of diagnostic imaging equiments, shortage of skilled workforce and unfavorable reimbusment structure of out patient imaging facilities in lower income countries are are anticipated to hamper the overall growth of the market. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17157849 Diagnostic Imaging Services Market Size, Growth by Procedure (MRI, Ultrasound, CT, X-RAY, Nuclear Imaging, Mammography), Application (OB/Gyn, Pelvic/Abdomen, Cardiology, Oncology, Neurology), Technology, User (Hospitals, Diagnostic Centers) - Global Forecast to 2027 The diagnostic imaging services market is segmented on application into general radiography, dentistry, and other X-ray applications. The general radiography segment will dominate the market during the forecast period. The large share of this application segment can be attributed to the rising prevalence of lung diseases globally and the increasing use of 3D X-ray imaging technogy in applications for chest, orthopedic & rheumatological, and cardiovascular imaging Based on end users, the diagnostic imaging services market is segmented into hospitals, diagnostic imaging centers, ambulatory care centers, and research & academia. In 2021, hospitals were the largest diagnostic imaging services market end users. The large share of the hospitals segment can be attributed to growing adoption of 3D imging technology, increasing adoption of minimally invasive procedures and ongoing collaboration with market players to adopt diagnostic imaging solutions. In April 2022, Siemens Healthineers (Germany) collaborated with Oulu University Hospital (Finland) to expand radiology solutions through supplying, installing, and maintaining medical imaging technology and software training in Finland. Based on region, the diagnostic imaging services market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the diagnostic imaging services market in 2021. The growth of the North American market is primarily driven by the strong foothold of key players in the region offering wide range of diagnostic imaging services. increased collbartion among imaging service providers and diagnostic centers , rapid adoption of highly adavanced imaging technology, and rising volume of imaging scans performed anully in the region. The major player in the market includes RadNet, Inc. (US), Sonic Healthcare (Australia), Akumin Inc. (US), Healius Limited (Australia), RAYUS Radiology (US), Dignity Health (US), Novant Health (US), Alliance Medical (UK), InHealth Group (UK), Apex Radiology (Australia), Concord Medical Services Holdings Limited (China), Unilabs (Switzerland), Affidea (Netherlands), I-MED Radiology Network (Australia), Capitol Imaging Services (US), SimonMed (US), among others Recent Developments: In 2022, Radnet, Inc. acquired Quantib and Aidence with an aim to expand its cancer screening portfolio for breast, prostate, and lung cancers through the integration of AI technology. In 2021 , Sonic Healthcare announced the acquisition of Canberra Imaging Group (Australia) to helped strengthen Sonic Healthcare’s geographic footprint in the Australian diagnostic imaging services market. In 2021, Akumin Inc. acquired Alliance Healthcare to enhance its diagnostic imaging service portfolio. -
-
Market Surge: Radiotherapy Expected to Hit $8.8 Billion by 2028 https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html The global radiotherapy market is valued at USD 6.9 billion in 2023 and is expected to reach USD 8.8 billion by 2028, at a CAGR of 5.0% during the forecast period. The expanding prevalence of cancer worldwide and the rising aging population has increased the demand for advanced and non-invasive cancer treatment. According to National Institute of Health (NIH), approximately 1,958,310 new cancer cases are expected to be registered in US by end of 2023. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567 Radiotherapy Market by Type (Product, Service), Technology(MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) - Global Forecast to 2028 Rising technological advancements in radiotherapy systems and software are playing a significant role in offering precise and personalized cancer treatment. Additionally, investments in oncology research activities by public & private organizations and initiatives by government to enhance the accessibility of radiotherapy devices are likely to contribute towards the significant growth of market during the forecast period. However, high cost associated with device procurement , limited financial budget, lack of health insurance coverage and inadequate healthcare infrastructure in low-income countries are likely to hinder the growth of radiotherapy market during the forecast period. On the basis of type, the radiotherapy market is segmented into products and software & services. The products segment accounted for the largest share of radiotherapy market in 2023. Whereas the software & services segment is anticipated to register a significant growth rate from 2023-2028. This is attributed to the adoption of treatment planning softwares allowing more precise and optimized radiation dose delivery. On the basis of technology, the radiotherapy market is segmented into external beam radiotherapy (further divided into linear accelerators, particle therapy systems, and conventional cobalt-60 teletherapy units, internal beam radiotherapy/brachytherapy (further segmented into seeds, applicators, after loaders, and IORT systems), and systemic radiotherapy products (including includes iobenguane (I-131), samarium-153, rhenium-186, and other radioisotopes (Yttrium-90, Radium-223, Phosphorous-32, and Radio-labelled antibodies, among others). In 2022, linear accelerators, a sub-segment of external beam radiotherapy segment accounted for the largest market This is attributed to the increased capabilities of LINAC in delivering effective radiation dosage, growing usage of LINAC across developed and developing nations, growing awareness about the advancements associated with LINAC systems. Based on end user, the radiotherapy market has been segmented into hospitals and independent radiotherapy centers. The hospitals segment accounted for the largest share of the radiotherapy market in 2023. This is attributed to the rising number of cancer patients undergoing radiotherapy treatment in hospitals and budget allocation implemented government in developing nation with an aim to enhance healthcare infrastructure, including the upgrading of radiotherapy equipment in hospitals. The global radiotherapy market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the radiotherapy market in 2022, followed by Europe. The larger share of North America is attribute to the strong adoption of advanced radiotherapy technology, presence of market players and favorable reimbursement policy in the region. The radiotherapy market in Asia Pacific is anticipated to experience significant growth opportunities in coming years owing to the government support for the development and commercialization of advanced radiotherapy devices , increased healthcare infrastructure, and rising number of cancer patients propelling demand for radiotherapy services across Asia Pacific Countries the radiotherapy market was dominated by Siemens Healthineers AG (Germany), Varian Medical Systems, Inc. (US), Elekta (Sweden) Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), Hitachi Ltd. (Japan), iCAD, Inc. (US), IsoRay, Inc. (US), , among others. Recent Developments of Radiotherapy Industry In October 2023, Accuray incorporated received approval of Tomo C radiation therapy system by the Chinese National Medical Products Administration (NMPA). In July 2023, IBA entered into partnership with Apollo Proton Cancer Centre (APCC) (India) to provide training to Oncologist on proton beam therapy In April 2022, Elekta and GE Healthcare entered into a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy -
-
Radiotherapy Market Growth: Driven by Technology, Awareness, and Patient Demand https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html The report "Radiotherapy Market by Type (Product, Service), Technology(MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) - Global Forecast to 2028", size is expected to grow from an estimated USD 6.9 billion in 2023 to USD 8.8 billion by 2028, at a CAGR of 5.0%. The growth of this market is majorly driven by factors such as the rapid rise in cancer cases globally, new developments in radiotherapy treatment such as adaptive radiotherapy, growing awareness about the advantages of proton therapy for cancer treatment. Moreover, increasing investments in research activities in the field of oncology, geographical expansion of radiotherapy devices manufacturers, improving healthcare infrastructure in developing countries are likely to support the growth of the market. -
-
Liv Pure Reviews is the ultimate prostate health supplement available only online. By chewing a Liv Pure Reviews tablet each day, you can use a blend of probiotics and herbal ingredients to stimulate urination, improve sleep, reduce urges, and support overall prostate health. Read our review to learn all about Liv Pure Reviews. hfitweb.com/liv-pure-reviews-does-liv-pure-work-livpure-weight-loss-pills/ -
-
Recent research has shown that PD-1 and PD-L1/PD-L2 pathway plays important roles in various cancers, including breast cancer, lung cancer, colorectal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, and DLBCL tumor. In this case, inhibitors targeting PD-1/PD-L1 have been reported for cancer therapy, and some of them are approved by FDA. Learn more: https://immune-checkpoint.creative-biolabs.com/pd-1-and-pd-l1-pd-l2-pathway.htm -
-
What Are The Symptoms Of Stage 1 Prostate Cancer? Prostate cancer is a common kind of cancer among men, and finding it early is very important for effective treatment. In the beginning phases, prostate cancer might not show clear signs, so having regular checks is necessary. This article explores the fine details of early symptoms for prostate cancer in stage 1 that might show it’s there and why taking care of health before problems appear is crucial. For more information Visit: https://www.punarjanayurveda.com/blog/what-are-the-symptoms-of-stage-1-prostate-cancer/
Copyright 2019 © P-tweets Refunds